Novartis AG Common Stock (NVS)

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

Truist, however, kept a ‘Buy’ rating on the shares.

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

The company is focused on treatments for forms of muscular dystrophy.

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This expansion reflects a persistent imbalance between what the nation imports and what it exports in goods, services, income,

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.